Table 2.

Primary multivariate survival analysis: rituximab plus chemotherapy versus chemotherapy alone

Variable/level	Hazard ratio (95% CI) (n = 1721)
Initial infused therapy
Chemotherapy alone	Reference
Rituximab plus chemotherapy	0.75 (0.62-0.91)
Age, y
66-69	Reference
70-74	1.35 (1.07-1.70)
75-79	1.62 (1.29-2.04)
≥ 80	2.31 (1.85-2.90)
Sex
Female	Reference
Male	1.34 (1.17-1.53)
Race/ethnicity
White	Reference
Black	1.32 (1.00-1.74)
Hispanic	1.12 (0.79-1.59)
Other	0.93 (0.59-1.45)
Stage
Not advanced	Reference
Advanced	1.40 (1.22-1.60)
NCI comorbidity score
0	Reference
1	1.09 (0.93-1.29)
2	1.16 (0.92-1.46)
≥ 3	1.44 (1.06-1.94)

Patients using rituximab monotherapy are excluded. Models are also adjusted for potential confounding from year of infusion, education, poverty, and metropolitan statistical area size.